中国正迎来减肥药爆发期。 过去三年,5 款GLP-1类减肥药相继在中国获批,叠加上百种在研药物储备,让前几年司美格鲁肽在减重领域的超适应证使用迅速成为历史。但随着药物种类快速扩容,临床规范、个性化用药的挑战逐渐显现。 近日,“玛仕度肽Dreams系列研究成果研讨会”在北京举办。会上,有专家提到中国糖尿病患者的肥胖表现有别于欧美人群,更多、更好的药物出现,能打破以往“生活方式干预效果有限”的局限...
Source Link中国正迎来减肥药爆发期。 过去三年,5 款GLP-1类减肥药相继在中国获批,叠加上百种在研药物储备,让前几年司美格鲁肽在减重领域的超适应证使用迅速成为历史。但随着药物种类快速扩容,临床规范、个性化用药的挑战逐渐显现。 近日,“玛仕度肽Dreams系列研究成果研讨会”在北京举办。会上,有专家提到中国糖尿病患者的肥胖表现有别于欧美人群,更多、更好的药物出现,能打破以往“生活方式干预效果有限”的局限...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.